Abstract: A method of wireless communication by a base station includes configuring a tracking reference signal (TRS) with respect to a physical downlink shared channel (PDSCH) for an idle/inactive mode user equipment (UE). The method also transmits the tracking reference signal and the PDSCH during a paging cycle, in accordance with the configuration. A method of wireless communication by a UE includes expecting a TRS to be received when a PDSCH is received.

Abstract: A method of wireless communication by a base station includes configuring a tracking reference signal (TRS) with respect to a physical downlink shared channel (PDSCH) for an idle/inactive mode user equipment (UE). The method also transmits the tracking reference signal and the PDSCH during a paging cycle, in accordance with the configuration. A method of wireless communication by a UE includes expecting a TRS to be received when a PDSCH is received.

Abstract: Provided are methods and articles of manufacture for use with cell therapy for the treatment of diseases or conditions, e.g., cancer, including for predicting and treating a toxicity. In some embodiments, the toxicity is a neurotoxicity or cytokine release syndrome (CRS), such as a severe neurotoxicity or a severe CRS. The methods generally involve detecting a marker by assaying a biological sample from a subject that is a candidate for treatment, optionally with a cell therapy, to determine if the subject is at risk for developing the toxicity, such as neurotoxicity or CRS or severe neurotoxicity or severe CRS. In some embodiments, the methods and articles of manufacture further includes a regent for assaying the biological sample and instructions for determining the percentage or number of cells positive for the marker in the biological sample.

Abstract: Trans-cyclooctene conjugates of immunomodulatory agents may be used for bioorthogonal delivery to a targeted location in a subject. The compositions and methods have applications in the treatment of cancer, tumor growths, and immunotherapy.

Abstract: Provided herein are methods of producing engineered T cell compositions enriched for CD57 negative and/or CD27 positive T cells, such as from a plurality of donors. In some embodiments, the T cells are engineered with a recombinant receptor, such as a chimeric antigen receptor (CAR). Also provided herein are engineered T cell compositions containing T cells enriched for CD57 negative and/or CD27 positive T cells derived from a plurality of different donors, including compositions in which the T cells are engineered with or express a recombinant receptor (e.g. CAR). Also provided are methods of using the engineered T cell compositions in adoptive therapy, including in connection for cancer immunotherapy, such as for allogeneic therapies or for administration to one or more subjects in which the T cells are not derived from the subject(s) to whom the compositions are administered.

Abstract: Trans-cyclooctene conjugates of therapeutic agents may be used for bioorthogonal delivery to a targeted location in a subject. The compositions and methods have applications in the treatment of various diseases or conditions including cancer, tumor growths, and bacterial infections.

Abstract: Cyclooctene conjugates of therapeutic or diagnostic agents have improved aqueous solubility and can release the agents upon contact with a tetrazine-containing biomaterial. The cyclooctene conjugates provide site-selective delivery of agents at the location of the tetrazine-containing biomaterial in a subject. The compositions and methods have applications in the treatment of various diseases or conditions including cancer, tumor growths, and bacterial infections.

Abstract: Cyclooctene conjugates of therapeutic or diagnostic agents have improved aqueous solubility and can release the agents upon contact with a tetrazine-containing biomaterial. The cyclooctene conjugates provide site-selective delivery of agents at the location of the tetrazine-containing biomaterial in a subject. The compositions and methods have applications in the treatment of various diseases or conditions including cancer, tumor growths, and bacterial infections.

Abstract: The present disclosure relates to processes for preparing functionalized cyclooctenes and the synthetic intermediates prepared thereby.

Abstract: A method of wireless communication by a base station includes configuring a tracking reference signal (TRS) with respect to a physical downlink shared channel (PDSCH) for an idle/inactive mode user equipment (UE). The method also transmits the tracking reference signal and the PDSCH during a paging cycle, in accordance with the configuration. A method of wireless communication by a UE includes expecting a TRS to be received when a PDSCH is received.

Abstract: Cyclooctene conjugates of therapeutic or diagnostic agents have improved aqueous solubility and can release the agents upon contact with a tetrazine-containing biomaterial. The cyclooctene conjugates provide site-selective delivery of agents at the location of the tetrazine-containing biomaterial in a subject. The compositions and methods have applications in the treatment of various diseases or conditions including cancer, tumor growths, and bacterial infections.

Abstract: Techniques are described herein that allow a user equipment (UE) to configure a subcarrier spacing value while monitoring synchronization signals of neighboring cells. In some wireless communication systems, synchronization signals in given radio frequency spectrum band may be transmitted using one of a plurality of different subcarrier spacings. In some cases, a network entity, such as a base station, may transmit an indication to the UE that indicates the subcarrier spacing used by a cell to transmit a specific set of synchronization signals. In some cases, the UE may select a subcarrier spacing based on a database of subcarrier spacings stored locally by the UE. In some cases, the UE may select the subcarrier spacing based on a predetermined configuration.

Abstract: The present disclosure provides methods for genetically engineering T cells, such as CD4+ T cells, for use in cell therapy. In some aspects, the provided methods include one or more steps for incubating the cells under stimulating conditions, introducing a recombinant polypeptide to the cells through transduction or transfection, and cultivating the cells under conditions that promote proliferation and/or expansion. In some aspects, the incubation and/or the cultivation is performed in the presence of recombinant IL-2. In some aspects, the provided methods are an efficient, reliable means to produce genetically engineered T cells with a high degree of success.

Abstract: Provided herein are methods, compositions and articles of manufacture for use in connection with cell therapy involving the administration of one or more doses of a therapeutic T cell composition. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the provided embodiments, including the numbers of cells or units of cells administered and/or the potency of administered cells, provide various advantages, such as lower risk of toxicity in subjects administered the T cell compositions.

Abstract: Provided are methods and articles of manufacture for use with cell therapy for the treatment of diseases or conditions, e.g., cancer, including for predicting and treating a toxicity. In some embodiments, the toxicity is a neurotoxicity or cytokine release syndrome (CRS), such as a severe neurotoxicity or a severe CRS. The methods generally involve detecting a marker by assaying a biological sample from a subject that is a candidate for treatment, optionally with a cell therapy, to determine if the subject is at risk for developing the toxicity, such as neurotoxicity or CRS or severe neurotoxicity or severe CRS. In some embodiments, the methods and articles of manufacture further includes a regent for assaying the biological sample and instructions for determining the percentage or number of cells positive for the marker in the biological sample.

Abstract: Techniques are described herein that allow a user equipment (UE) to configure a subcarrier spacing value while monitoring synchronization signals of neighboring cells. In some wireless communication systems, synchronization signals in given radio frequency spectrum band may be transmitted using one of a plurality of different subcarrier spacings. In some cases, a network entity, such as a base station, may transmit an indication to the UE that indicates the subcarrier spacing used by a cell to transmit a specific set of synchronization signals. In some cases, the UE may select a subcarrier spacing based on a database of subcarrier spacings stored locally by the UE. In some cases, the UE may select the subcarrier spacing based on a predetermined configuration.

Abstract: A mobile station that is configured to perform common channel cancellation may include a parameter estimation unit that is configured to estimate parameters for generating a common channel error. The mobile station may also include a common channel generation unit that is configured to generate the common channel error based on the parameters. The mobile station may also include an adder that is configured to subtract the common channel error from received data samples.

Abstract: The present invention is directed to a method for the preparation of macrocyclic compounds of formula (I), comprising the step of cyclizing a diene of formula (II), in the presence of a catalyst, wherein R1-R6, A, W and V are as defined herein. The present invention is also directed to intermediate compounds of formula II.

Abstract: A mobile station that is configured to perform common channel cancellation may include a parameter estimation unit that is configured to estimate parameters for generating a common channel error. The mobile station may also include a common channel generation unit that is configured to generate the common channel error based on the parameters. The mobile station may also include an adder that is configured to subtract the common channel error from received data samples.

Abstract: Techniques for controlling transmit power are described. Due to link imbalance, a downlink (DL) serving cell may have the best downlink for a UE, and an uplink (UL) serving cell may have the best uplink for the UE. In one design of UL power control, the UE receives first and second UL TPC commands from the DL and UL serving cells, respectively, and adjusts its transmit power based on these UL TPC commands and in accordance with an OR-of-the-UPs rule. In one design of DL power control, the UE generates a DL TPC command based on received signal qualities of both the DL and UL serving cells. In another design, power control is performed independently for the DL and UL serving cells. The UE generates a separate DL TPC command for each cell, which adjusts its transmit power based on the DL TPC command for that cell.